3rd Conf Retro and Opportun Infect. 1996 Jan 28-Feb 1;:162. Unique
A subset of 230 Delta1 -AZT naive-patients were recruited in 22 selected
centers in France, UK and Netherlands for virological studies including
viral load quantitation. Quantitative cellular and plasma viremia were
performed by a consensus methodology at week -2, 0, 4, 12, 24, 48, 64
and 96. Plasma RNA measurement was assayed by the Monitor Roche
Molecular Systems assay on specimens collected twice at baseline,
monthly up to W16, every two months until W64, then every four months.
Of the 230 patients, 85 had been randomised to Zidovudine (AZT)
monotherapy, 73 to AZT + didanosine (ddl) and 72 to AZT +
Zalcitabine(ddC). At baseline, the virology subset patients had a mean
and a median CD4 cell count of 210 [IQR: 123-280]; 52% were
asymptomatic, 31% had ARC and 17% AIDS. Quantitative cellular and plasma
viremia were positive in 91% and 61.6% of the patients respectively.
Changes in quantitative cultures and RNA viral load will be reported.
Antiviral Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE CD4
Lymphocyte Count Didanosine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE
Drug Therapy, Combination HIV Infections/BLOOD/*DRUG THERAPY
HIV-1/GENETICS/*ISOLATION & PURIF Human RNA, Viral/BLOOD
Zalcitabine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE
Zidovudine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE ABSTRACT